Blocking LINGO-1 as a therapy to promote CNS repair: From concept to the clinic

CNS Drugs

Volumn 27, Issue 7, 2013, Pages 493-503

  Mi, Sha ^a   Blake Pepinsky, R ^a   Cadavid, Diego ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FC RECEPTOR; IMMUNOGLOBULIN G1; LINGO 1 PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BIIB033; MYELIN BASIC PROTEIN; OXIDOPAMINE; PROTEIN; PROTEIN KINASE B; RAS PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEMYELINATION; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; GLAUCOMA; HUMAN; IN VIVO STUDY; INTRAOCULAR PRESSURE; MULTIPLE SCLEROSIS; MYELINATION; NERVE CELL DIFFERENTIATION; NERVE REGENERATION; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REMYELINIZATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPINAL CORD INJURY; UPREGULATION; WHITE MATTER;

AGING; ANIMALS; ANTIBODIES, MONOCLONAL; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; NEURONS; OLIGODENDROGLIA; SIGNAL TRANSDUCTION;

EID: 84880521310     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0068-8     Document Type: Article

References (61)

1. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011;10(5):377-93.
2. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.
3. Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics. 2007;25(4):287-308.
4. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011;93(1):1-12.
5. Chen Y, Aulia S, Li L, et al. AMIGO and friends: an emerging family of brain-enriched, neuronal growth modulating, type I transmembrane proteins with leucine-rich repeats (LRR) and cell adhesion molecule motifs. Brain Res Rev. 2006;51(2):265-74.
6. Kuja-Panula J, Kiiltomaki M, Yamashiro T, et al. AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats. J Cell Biol. 2003;160(6):963-73.
7. Nguyen-Ba-Charvet KT, Picard-Riera N, Tessier-Lavigne M, et al. Multiple roles for slits in the control of cell migration in the rostral migratory stream. J Neurosci. 2004;24(6):1497-506.
8. Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature. 2001;409(6818):341-6.
9. McGee AW, Strittmatter SM. The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci. 2003;26(4):193-8.
10. Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci. 2004;7(3):221-8.
11. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8(6):745-51.
12. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13(10):1228-33.
13. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65(3):304-15.
14. Inoue H, Lin L, Lee X, et al. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci USA. 2007;104(36):14430-5.
15. Fu QL, Hu B, Wu W, et al. Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest Ophthalmol Vis Sci. 2008;49(3):975-85.
16. Lee X, Yang Z, Shao Z, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci. 2007;27(1):220-5.
17. Fu QL, Hu B, Li X, et al. LINGO-1 negatively regulates TrkB phosphorylation after ocular hypertension. Eur J Neurosci. 2010;31(6):1091-7.
18. Fu QL, Li X, Yip HK, et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience. 2009;162(2):375-82.
19. Ji B, Li M, Wu WT, et al. LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci. 2006;33(3):311-20.
20. Mi S, Sandrock A, Miller RH. LINGO-1 and its role in CNS repair. Int J Biochem Cell Biol. 2008;40(10):1971-8.
21. Rudick RA, Mi S, Sandrock AW Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther. 2008;8(10):1561-70.
22. Barrette B, Vallieres N, Dube M, et al. Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system. Mol Cell Neurosci. 2007;34(4):519-38.
23. Carim-Todd L, Escarceller M, Estivill X, et al. LRRN6A/LERN1 (leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex. Eur J Neurosci. 2003;18(12):3167-82.
24. Okafuji T, Tanaka H. Expression pattern of LINGO-1 in the developing nervous system of the chick embryo. Gene Expr Patterns. 2005;6(1):57-62.
25. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221-31.
26. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52(1):61-76.
27. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-9.
28. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci. 2002;3(9):705-14.
29. Franklin RJ. Remyelination of the demyelinated CNS: the case for and against transplantation of central, peripheral and olfactory glia. Brain Res Bull. 2002;57(6):827-32.
30. Franklin RJ, Hinks GL. Understanding CNS remyelination: clues from developmental and regeneration biology. J Neurosci Res. 1999;58(2):207-13.
31. Chang A, Tourtellotte WW, Rudick R, et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med. 2002;346(3):165-73.
32. Lau LW, Keough MB, Haylock-Jacobs S, et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol. 2012;72(3):419-32.
33. Kotter MR, Li WW, Zhao C, et al. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci. 2006;26(1):328-32.
34. Fancy SP, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 2009;23(13):1571-85.
35. Back SA, Tuohy TM, Chen H, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med. 2005;11(9):966-72.
36. Zhang Y, Argaw AT, Gurfein BT, et al. Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc Natl Acad Sci USA. 2009;106(45):19162-7.
37. Chan JR, Watkins TA, Cosgaya JM, et al. NGF controls axonal receptivity to myelination by Schwann cells or oligodendrocytes. Neuron. 2004;43(2):183-91.
38. Mi S, Cadavid D. A novel CNS remyelination and repair therapy by blocking LINGO-1 pathway. In: 26th congress of european committee for treatment and research in multiple sclerosis, Gothenburg, 12-16 Oct 2010, p. P731.
39. Papadopoulos D, Pham-Dinh D, Reynolds R. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol. 2006;197(2):373-85.
40. Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther. 2011;339(2):519-29.
41. Pallini R. Anatomy of "regenerating axons". Science. 1998;280(5361):181-2.
42. Park JB, Yiu G, Kaneko S, et al. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron. 2005;45(3):345-51.
43. Shao Z, Browning JL, Lee X, et al. TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron. 2005;45(3):353-9.
44. Lv J, Xu RX, Jiang XD, et al. Passive immunization with LINGO-1 polyclonal antiserum afforded neuroprotection and promoted functional recovery in a rat model of spinal cord injury. Neuroimmunomodulation. 2010;17(4):270-8.
45. Ericson C, Georgievska B, Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci. 2005;22(11):2755-64.
46. Hanke M, Farkas LM, Jakob M, et al. Heparin-binding epidermal growth factor-like growth factor: a component in chromaffin granules which promotes the survival of nigrostriatal dopaminergic neurones in vitro and in vivo. Neuroscience. 2004;124(4):757-66.
47. Iwakura Y, Piao YS, Mizuno M, et al. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. J Neurochem. 2005;93(4):974-83.
48. Seroogy KB, Numan S, Gall CM, et al. Expression of EGF receptor mRNA in rat nigrostriatal system. Neuroreport. 1994;6(1):105-8.
49. Wang X, McCullough KD, Franke TF, et al. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem. 2000;275(19):14624-31.
50. Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36(5):774-86.
51. Tran J. BIIB033 phase I study. In: Annual meeting of the American Academy of Neurology, New Orleans. 21-28 2012, p. P02-021.
52. Bongioanni P, Reali C, Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2004;(3):CD004302.
53. Lavail MM. Survival factors for treatment of retinal degenerative disorders: preclinical gains and issues for translation into clinical studies. Retina. 2005;25(8 Suppl.):S25-6.
54. Sahenk Z. Neurotrophins and peripheral neuropathies. Brain Pathol. 2006;16(4):311-9.
55. Sarchielli P, Gallai V. Nerve growth factor and chronic daily headache: a potential implication for therapy. Expert Rev Neurother. 2004;4(1):115-27.
56. Sherer TB, Fiske BK, Svendsen CN, et al. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord. 2006;21(2):136-41.
57. Tuszynski MH. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):179-89.
58. Williams BJ, Eriksdotter-Jonhagen M, Granholm AC. Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. Prog Neurobiol. 2006;80(3):114-28.
59. Woodruff RH, Fruttiger M, Richardson WD, et al. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci. 2004;25(2):252-62.
60. Zazpe A, Del Rio J. Neurotrophins. II: therapeutic potential. Rev Med Univ Navarra. 1997;41(3):180-4.
61. Zhang J, Lineaweaver WC, Oswald T, et al. Ciliary neurotrophic factor for acceleration of peripheral nerve regeneration: an experimental study. J Reconstr Microsurg. 2004;20(4):323-7.